Patent 7036931 was granted and assigned to Novartis on May, 2006 by the United States Patent and Trademark Office.
The present invention provides an ophthalmic lens capable of correcting or minimizing presbyopia, or of functioning used as an anti-myopic lens. The ophthalmic lens can be a contact lens, a phakic intraocular lens or an aphakic intraocular lens. The ophthalmic lens comprises an optical zone, the optical zone having a first surface and an opposite second surface and including a coma-like wavefront aberration oriented vertically from the top to the bottom of the ophthalmic lens. In addition, the present invention provides a method for minimizing/correcting presbyopia or for preventing children's eyes from becoming severely myopic.